CAS: 1196-57-2; 2-Quinoxalinol

相似化合物

82031-32-1 55687-23-5 14003-34-0

上下游产品

CAS号924-44-7 乙醛酸乙酯 | CAS号95-54-5 邻苯二胺(OPD) | CAS号298-12-4 乙醛酸 | CAS号14003-34-0 3-甲基喹喔啉-2-醇 | CAS号34836-97-0 6-chloro-1,2-di... | CAS号96-35-5 乙醇酸甲酯 | CAS号1222-71-5 3-(Dr-1tF,2cF,3... | CAS号2423-66-7 喹喔啉1,4-二氧化物 | CAS号34797-69-8 对氯邻硝基乙酰乙酰苯胺 | CAS号1065484-81-2 2-(6-Chloro-pyr... | CAS号59564-59-9 3,4-二氢喹喔啉-2(1H)-酮 | CAS号55687-34-8 6-溴喹喔啉-2(1H)-酮 | CAS号55687-02-0 6-溴-2-氯喹恶啉 | CAS号55686-94-7 2-氯-7-硝基喹啉 | CAS号143007-11-8 7-nitro-5H-tetr... | CAS号36856-91-4 2-溴喹喔啉 | CAS号21948-73-2 Quinoxaline,2-(... | CAS号2712-12-1 Quinoxaline, 2-... | CAS号25652-34-0 2-羟基-6-硝基喹喔啉

喹多克辛置于sodium Dithionite,乙酸酐体系中,用 乙醇,水 用作溶剂,化学反应 16.0H,反应生成2-羟基喹喔啉
参考文献:喹喔啉衍生物.十二. 喹喔啉1,4-二氧化物与乙酸酐的反应
标题:喹喔啉衍生物.十二. 喹喔啉1,4-二氧化物与乙酸酐的反应
摘要:喹喔啉 1,4-二氧化物 (Xiiia) 与乙酸酐反应生成1-乙酰氧基-2(1H)-喹喔啉酮 (Xiva),其易于水解反应生成1-羟基-2(1H)-喹喔啉酮 (Xva).Xiva和xva均从反应混合物中分离.在与乙酸酐一起长时间加热后,Xiiia,Xiva 和 Xva 缓慢转化为相同的最终产物,2,3(1H,4H)-喹喔啉二酮 (Xxa).6-乙氧基-(Xiiib),6-甲氧基-(Xiiic) 和 6-甲基喹喔啉 1,4-二氧化物 (Xiiid) 的行为相似,不同之处在于试剂的攻击仅发生在电子对位的 N-氧化物上.提供取代基,并且没有分离出其他预期的异构化合物 Xviib-D.而在苯环上带有吸电子氯取代基的 6-氯喹喔啉 1,4-二氧化物 (Xiiie) 仅产生其他异构体 Xviie,Xviiie 和 Xxe.
Doi:10.1246/bcsj.60.1145

专利信息

专利号:WO-2023233371-A1
优先权日:2022-06-03
标 题:A continuous flow process for synthesis of organic azides
发明人：GNANAPRAKASAM BOOPATHY; PANDEY AKANKSHA M; MONDAL SHANKHAJIT
权利人:INDIAN INSTITUTE OF SCIENCE EDUCATION AND RES PUNE IISER PUNE
摘要:The present disclosure relates generally to the field of synthetic organic chemistry. More specifically, the disclosure is directed to a continuous flow process for synthesis of azides from alcohols and peroxides, wherein the process comprises azidation with trimethylsilyl azide and a catalyst Amberlyst-15. It is a non-hazardous, mild and controlled reaction giving good yields of azides. The azides can be further employed for synthesis of medicinally and industrially useful chemicals.

专利号:US-2001044540-A1
优先权日:2000-03-23
标 题:Asymmetric synthesis of quinazolin-2-ones useful as HIV reverse transcriptase inhibitors
发明人：PARSONS RODNEY L; DOROW ROBERTA L; DAVULCU AKIN H; FORTUNAK JOSEPH M; HARRIS GREGORY D; KAUFFMAN GOSS S; NUGENT WILLIAM A; RADESCA LILIAN A
摘要:This invention relates generally to the asymmetric synthesis of quinazolin-2-ones that are useful as inhibitors of HIV reverse transcriptase. The synthesis is accomplished through the chiral ligand mediated addition of cyclopropylacetylide.

专利号:US-9708317-B2
优先权日:2013-11-25
标 题 :Process for the preparation of 8-(4-aminophenoxy)-4H-pyrido[2,3-B]pyrazin-3-one derivatives
发明人：ZAMBON ALFONSO; NICULESCU-DUVAZ DAN; CHUBB RICHARD; SPRINGER CAROLINE JOY
权利人:CANCER RES TECH LTD; INST OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE); OXY SCIENT LTD; THE INST OF CANCER RESEARCH: ROYAL CANCER HOSPITAL
摘要:The present invention pertains generally to the field of organic chemical synthesis, and in particular to certain methods for the synthesis of 8-(4-aminophenyoxy)-4H-pyrido[2,3-b]pyrazin-3-one and related compounds (denoted herein as (3)) from 4-(4-aminophenyoxy)pyridine-2,3-diamine and related compounds (denoted herein as (1)), by reaction with glyoxylic acid (denoted herein as (2)). The compounds (3) are useful in the synthesis of known anti-cancer agents, such as 1-(5-tert-butyl-2-(4-methyl-phenyl)-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido[2,3-b]pyrazin-8-yl)oxy]phenyl]urea.

专利号:US-6555686-B2
优先权日:2000-03-23
标题:Asymmetric synthesis of quinazolin-2-ones useful as HIV reverse transcriptase inhibitors
发明人：PARSONS RODNEY L; DOROW ROBERTA L; DAVULCU AKIN H; FORTUNAK JOSEPH M; HARRIS GREGORY D; KAUFFMAN GOSS S; NUGENT WILLIAM A; RADESCA LILIAN A
权利人:BRISTOL MYERS SQUIBB PHARMA
摘要:This invention relates generally to the asymmetric synthesis of quinazolin-2-ones that are useful as inhibitors of HIV reverse transcriptase. The synthesis is accomplished through the chiral ligand mediated addition of cyclopropylacetylide.

专利号:US-2004101523-A1
优先权日:1989-07-27
标题:Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension
发明人：REITZ DAVID B; KOEPKE JOHN P; BLAINE EDWARD H; SCHUH JOSEPH R; MANNING ROBERT E; SMITS GLENN J
权利人:SEARLE & CO
摘要:Renal-selective prodrugs are described which are preferentially converted in the kidney to compounds capable of inhibiting synthesis of catecholamine-type neurotransmitters involved in renal sympathetic nerve activity. The prodrugs described herein are derived from inhibitor compounds capable of inhibiting one or more of the enzymes involved in catecholamine synthesis, such compounds being classifiable as tyrosine hydroxylase inhibitors, or as dopa-decarboxylase inhibitors, or as dopamine-β-hydroxylase inhibitors. These inhibitor compounds are linked to a chemical moiety, such as a glutamic acid derivative, by a cleavable bond which is recognized selectively by enzymes located predominantly in the kidney. The liberated inhibitor compound is then available in the kidney to inhibit one or more of the enzymes involved in catecholamine synthesis. Inhibition of renal catecholamine synthesis can suppress heightened renal nerve activity associated with sodium-retention related disorders such as hypertension. Conjugates of particular interest are glutamyl derivatives of dopamine-β-hydroxylase inhibitors, of which N-acetyl-γ-glutamyl fusaric acid hydrazide (shown below) is preferred.

专利号:WO-9101724-A1
优先权日:1989-07-27
标题 :Renal-selective prodrugs for the treatment of hypertension
发明人：REITZ DAVID B; KOEPKE JOHN P; BLAINE EDWARD H; SCHUH JOSEPH R; MANNING ROBERT E; SMITS GLENN J
权利人:SEARLE & CO
摘要:Renal-selective prodrugs are described which are preferentially converted in the kidney to compounds capable of inhibiting synthesis of catecholamine-type neurotransmitters involved in renal sympathetic nerve activity. The prodrugs described herein are derived from inhibitor compounds capable of inhibiting one or more of the enzymes involved in catecholamine synthesis, such compounds being classifiable as tyrosine hydroxylase inhibitors, or as depa-decarboxylase inhibitors, or as dopamine-β-hydroxylase inhibitors. These inhibitors compounds are linked to a chemical moiety, such as a glutamic acid derivative, by a cleavable bond which is recognized selectively by enzymes located predominantly in the kidney. The liberated inhibitor compound is then available in the kidney to inhibit one or more of the enzymes involved in catecholamine synthesis. Inhibition of renal catecholamine synthesis can suppress heightened renal nerve activity associated with sodium-retention related disorders such as hypertension. Conjugates of particular interest are glutamyl derivatives of dopamine-β-hydroxylase inhibitors, of which N-acetyl-Y-glutamyl fusaric acid is preferred.